Navigation Links
Intercell to Webcast Research & Development Day on Thursday, June 4, 2009
Date:5/27/2009

VIENNA and GAITHERSBURG, Md., May 27 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that it will webcast its Research & Development Day being held in New York on Thursday, June 4 starting at 12:00 p.m. Eastern Time (6 pm CET, 5 pm GMT).

"This year's meeting will focus on the applications we are pursuing with our novel, needle-free vaccine patch technology," said Gerd Zettlmeissl, Chief Executive Officer of Intercell. "Our proprietary vaccine technology platforms have yielded a rich pipeline of products and enabled us to partner with leading pharmaceutical companies. We also look forward to providing an update on the launch of IXIARO(R), our novel vaccine to prevent Japanese Encephalitis, as well as our other partnered programs."

The featured speaker at the meeting is Dr. Herbert DuPont, a specialist in infectious disease and the primary investigator for the Intercell Travelers' Diarrhea Phase II clinical trial. Dr. Dupont will discuss the need for new vaccines particularly for travelers. Dr. DuPont currently serves as director for the Center for Infectious Diseases at The University of Texas Health Science Center, School of Public Health. He also holds positions as the chief of internal medicine at St. Luke's Episcopal Hospital in Houston and the Baylor College of Medicine H. Irving Schweppe, Jr., MD, chair in internal medicine. Dr. DuPont has been a director of the National Foundation of Infectious Diseases since 1981 and a vice president of the Foundation for the past three years.

In addition to Dr. DuPont, members of the Intercell management team will make presentations including, Gerd Zettlmeissl, Chief Executive Officer of Intercell AG, Thomas Lingelbach, Chief Operating Officer of Intercell AG, Reinhard Kandera, Chief Financial Officer of Intercell AG, Alexander von Gabain, Chief Scientific Officer of Intercell AG and Gregory M. Glenn, Chief Scientific Officer of Intercell USA.

Webcast Details

The slide and audio presentation will be available live from the investor relations section of the company's website at www.intercell.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled webcast (in addition, the webcast will be archived on www.intercell.com).

    Agenda

    -- Introduction & Strategic Overview
       Gerd Zettlmeissl, CEO Intercell AG

    -- Travelers' Diarrhea: Vaccination and the importance of prevention
       Prof. Herbert DuPont, Guest speaker
       Professor and Director of the Center for Infectious Diseases,
       University of Texas, School of Public Health

    -- Intercell's Vaccine Patch Technology
       Gregory M. Glenn, CSO Intercell USA, Inc.

    -- Business Update
       Thomas Lingelbach, COO Intercell AG

    -- Scientific Update
       Alexander von Gabain, CSO Intercell AG

    -- Financial Update & Outlook
       Reinhard Kandera, CFO Intercell AG

About Intercell AG

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product on the market.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, and Sanofi Pasteur.

The Company's pipeline includes a Travelers' Diarrhea Vaccine Patch (Phase II concluded), a Pseudomonas vaccine candidate (Phase II), a Vaccine Enhancement Patch to prevent Pandemic Influenza in combination with an injected vaccine, a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, three other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit: www.intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


'/>"/>
SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military
2. Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
3. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
4. DiagnoCure to host Q2 2009 earnings conference call and webcast
5. Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders
6. Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009
7. Thoratec Presentation at JMP Securities Conference to be Webcast
8. CorVel Announces Fiscal Year Earnings Release Webcast
9. Volcano Corporation Presentation at JMP Conference to be Webcast
10. Aon to Webcast Annual Shareholders Meeting
11. Video: Hope Solution Organizations First National Change That Matters Webcast Telethon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, ... INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... BEIJING , Dec. 2, 2016 ... ("Lianluo Smart" or "the Company") which develops, markets ... products in China and ... Cardiovascular Disease Diagnosis and Treatment New Progress Forum, ... Guangdong Province , Guangdong Provincial ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... and Companies" to their offering. ... , , Drug ... market value of drug delivery technologies and the anticancer drugs are ... to organs involved and the types of cancer as well as ...
Breaking Medicine Technology: